Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. (NYSE: STXS) is active in surgical robotics and medical device innovation, and its news flow reflects ongoing developments in minimally invasive endovascular intervention and cardiac electrophysiology. Company announcements frequently highlight regulatory milestones, product clearances, clinical adoption, and capital markets activity, making the STXS news page a focused resource for tracking these events in one place.
Recent news releases describe U.S. Food and Drug Administration approval of the MAGiC Magnetic Interventional Ablation Catheter, FDA 510(k) clearance for the GenesisX Robotic Magnetic Navigation system, and CE Mark in Europe for the Synchrony digital cath lab system along with a 510(k) submission to the FDA. Other updates cover the commercial launch and first procedures using the MAGiC Sweep high-density electrophysiology mapping catheter, as well as clinical use of the Genesis system at leading medical centers.
Investors and clinicians following STXS can also find news on collaborations, such as the agreement with CardioFocus to advance a robotic pulsed field ablation solution for cardiac arrhythmias. Financial and investor-relations updates, including quarterly earnings press releases and participation in healthcare and growth conferences, are regularly communicated through company news.
This page aggregates these categories of information—regulatory clearances, product launches, clinical milestones, collaborations, and financial communications—so readers can monitor how Stereotaxis’ robotic systems, catheters, and digital cath lab technologies progress over time. For anyone tracking STXS stock or the evolution of its technology portfolio, the news feed offers a structured view of the company’s publicly reported developments.
Stereotaxis (NYSE: STXS) announced that BJC HealthCare has installed the Genesis RMN system at Missouri Baptist Medical Center, making it the first healthcare system in the Midwest to offer this advanced robotic technology for cardiac arrhythmia treatment. A second installation is planned at Barnes-Jewish Hospital. The Genesis RMN system enhances cardiac ablation procedures with robotic precision, improving safety and effectiveness. With a history of over 1,000 treatments at Barnes-Jewish Hospital, this partnership aims to expand access to innovative arrhythmia care in the St. Louis region.
Stereotaxis reported a 5% increase in revenue for Q3 2021, totaling $9.1 million, driven by renewed adoption of robotic systems. Operating expenses rose to $9.4 million, reflecting increased R&D and hiring. Both operating and net losses were $4.6 million, worsening from $1.6 million the previous year. The company maintains a cash balance of $42.8 million, down from $44.2 million at year-end 2020. Strategic collaborations, especially in China, and upcoming innovations are positioned to enhance long-term growth.
Stereotaxis (NYSE: STXS) has announced its participation in the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) on November 12-13, 2021. This hybrid event will showcase discussions on innovations in cardiac robotics, including presentations on energy sources, automated navigation for atrial fibrillation, and TeleRobotic collaborations. The SCRN aims to foster clinical awareness and technology advancement in cardiology. Stereotaxis continues to lead in robotic technology for arrhythmias, emphasizing its commitment to improving patient care.
Stereotaxis (NYSE: STXS) announced it will release its 2021 third quarter financial results on November 11, 2021, before U.S. markets open. A conference call will follow at 10 a.m. EST to discuss results and corporate updates. Investors can access the call by dialing 800-367-2403 (U.S. and Canada) or 334-777-6978 (International), using passcode 1935969. A webcast will also be available on the company’s investor relations webpage.
Stereotaxis (NYSE: STXS) announced the installation of its Genesis Robotic Magnetic Navigation system at Princess Grace Hospital Center in Monaco, enhancing the treatment of cardiac arrhythmias. This system is pivotal for robotic cardiac ablation, which has treated over 1,000 patients in Monaco since its introduction in 2006. The hospital's electrophysiologists, key early adopters of this technology, have already successfully treated patients with the new system. Stereotaxis emphasizes its long-term partnership with the hospital and its commitment to advancing electrophysiology technology.
On October 12, 2021, Stereotaxis (NYSE: STXS) announced a publication highlighting their robotic technology's effectiveness in treating cardiac arrhythmias in pediatric patients. The study, which included 223 patients and was conducted at Erasmus Medical Center, revealed that patients receiving Robotic Magnetic Navigation (RMN) had a 94.4% success rate in avoiding arrhythmia recurrence over a mean follow-up of 5.5 years. Notably, zero adverse events occurred with RMN, contrasting with 2.6% for manual methods, showcasing significant safety and efficacy benefits.
Stereotaxis (NYSE: STXS), a leader in robotic technologies for cardiac arrhythmia treatment, announced presentations by CEO David Fischel at two investor conferences in September 2021. He will attend the Lake Street 5th Annual Best Ideas Growth Conference on September 15 for one-on-one meetings, and present at the Cantor Virtual Global Healthcare Conference on September 29 at 8:00 am EDT, also available for one-on-one meetings. Fischel aims to discuss Stereotaxis’ technology, clinical value, and growth strategy.
Stereotaxis (NYSE: STXS) and MicroPort EP have announced a strategic collaboration to enhance robotics technology in electrophysiology in China. MicroPort EP will serve as the exclusive distributor of Stereotaxis’ Robotic Magnetic Navigation technology in the region. This partnership aims to integrate advanced technologies like the Genesis RMN® system and develop new cardiac catheters. The agreement, effective until 2028, intends to significantly boost the adoption of robotic systems in China’s electrophysiology market, benefiting healthcare providers and patients alike.
Stereotaxis reported strong financial results for Q2 2021, with revenue of $9.1 million, marking a 70% increase year-over-year. System revenue reached $2.7 million, supported by new orders in the US and China. Recurring revenue also grew to $6.1 million, up from $5.1 million. The company faced operating losses of $3.4 million but reported a net loss of $1.2 million, benefiting from $2.2 million in Paycheck Protection Loan forgiveness. Cash balance remained stable at $44.2 million as of June 30, 2021.
Stereotaxis (NYSE: STXS) has appointed Dr. Myriam J. Curet to its Board of Directors. Dr. Curet, currently Chief Medical Officer at Intuitive Surgical, brings over 20 years of experience in robotic surgery. She has been instrumental in developing clinical evidence and regulatory support at Intuitive Surgical. Dr. Curet expressed her excitement about Stereotaxis’ technology and its potential to transform endovascular medicine. CEO David Fischel welcomed her expertise as the company advances its robotics initiatives.